Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting

Zurich-Schlieren, Switzerland, April 16, 2019. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin^® therapeutics to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority.

At today’s Annual General Meeting of Molecular Partners AG, Bill Burns, Göran Ando, Gwen Fyfe, Steven H. Holtzman, William A. Lee, Petri Vainio and Patrick Amstutz were re-elected as members of the Board of Directors for a term of office until the 2020 Annual General Meeting. Bill Burns was re-elected as Chairman of the Board of Directors. The shareholders also elected the three proposed members of the Nomination and Compensation Committee – Bill Burns, Göran Ando and William A. Lee.

KPMG AG Zurich was re-elected as the Group’s statutory auditors for the financial year 2019 and Anwaltskanzlei Keller KLG, Zurich, elected as the independent proxy for a term of office until the 2020 Annual General Meeting.

The Annual General Meeting approved all (binding) motions regarding compensation of the Board of Directors and the Management Board. Further, the shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2018, the appropriation of the 2018 results, as well as the compensation report (in a consultative vote). The Board of Directors and the Management Board were granted discharge for the financial year 2018.

Financial Calendar

May 9, 2019
Interim Management Statement Q1 2019
August 27, 2019
Publication of Half-year Results 2019 (unaudited)
October 31, 2019
Interim Management Statement Q3 2019